TPWA
GMAB icon

Twin Peaks Wealth Advisors’s Genmab GMAB Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.68K Buy
+249
New +$7.46K ﹤0.01% 1265
2025
Q3 		– Sell
-187
Closed -$4.09K – 948
2025
Q2 		$4.09K Buy
+187
New +$3.84K ﹤0.01% 1390

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Twin Peaks Wealth Advisors's GMAB Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Genmab (GMAB) in Q1 2026: 249 shares worth $6.68K. The stake represents ﹤0.01% of the portfolio and ranks #1265 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in GMAB as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in GMAB in Q2 2025 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Twin Peaks Wealth Advisors held 249 shares of Genmab worth $6.68K as of Q1 2026.
  • Genmab was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Genmab made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1265 holding.
  • Twin Peaks Wealth Advisors first reported a position in Genmab in Q2 2025 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.